Introduction
The congenital long-QT syndrome (LQTS) is a genetic disorder characterized by a prolonged QT interval and by life-threatening arrhythmias particularly in association with emotional and physical stress. 1, 2 The main genetic subgroups are LQT1, LQT2, and LQT3, respectively due to mutations on the genes KCNQ1, KCNH2, and SCN5A affecting potassium and sodium currents and accounting for 90% of all genotype-positive cases. 3 Despite an overall efficacy of b-blocker therapy in all three subgroups 2 with best results for LQT1, 2 LQT2
patients, especially females, remain at higher risk through life. 4 The implantable cardioverter-defibrillator (ICD) saves lives but carries high percentage of serious complications, over 30% within 4 years, 5 with a negative impact on the quality of life. Thus, there is an unmet need for a more targeted and effective pharmacological management for LQT2 patients. Current gold standards of heterologous expression systems and genetic animal models for LQT2 study are unable to completely recapitulate the distinct and complex electrophysiological features of human cardiomyocytes. 6 Following the pioneering study by Moretti et al., 7 we and others have shown that human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) recapitulate the LQTS disease phenotype, [7] [8] [9] thus offering a unique platform to test novel compounds as potential therapeutics. [6] [7] [8] [9] Long-QT syndrome type 2 is primarily a K þ channel disorder as loss-of-function KCNH2 mutations decrease the rapidly activating delayed rectifier K þ current (I Kr ) in the heart. The extent of I Kr reduction is mutation specific and occurs largely through disruption of the synthesis/translation of Kv11.1 a-subunits (Class 1) or through reduction of the intracellular transport or trafficking of Kv11.1/hERG proteins to the cell membrane (Class 2). Finally, Class 3 and 4 mutations disrupt Kv11.1 channel gating and permeation. 10 The cascade of events involved in arrhythmias onset in LQT2 has not yet been fully understood, and it has been proposed that the remodelling of Ca 2þ signalling pathways 11 might also play an important role. While interplay of action potential and Ca 2þ release from sarcoplasmic reticulum (SR) via ryanodine receptors (RyR) is vital for rhythmic cardiac cycle, maladaptive changes in Ca 2þ homeostasis represent one of the mechanisms triggering arrhythmias in LQT2.
Here, we used iPSC-CMs generated from the fibroblasts of five LQT2 patients bearing different mutations to validate a targeted pharmacological approach. Specifically, we tested whether 
Methods

Patient and control characteristics
We enrolled five LQT2 patients who experienced life-threatening arrhythmic episodes at least once in their life, had a very high 'Schwartz Score' (a marker of diagnostic probability 2 ) and were carriers of four different disease-causing mutations listed in Table 1 .
Case 1 and Case 2 are classified as Class 1 mutation due to their premature termination codons 13, 14 while Case 3, 4, and 5 are classified as Class 2 mutations. 8, 15 We also included two healthy donors as controls in Singapore. Four patients were enrolled in Italy, one in Singapore. The study was performed in accordance with the declaration of Helsinki, and all protocols were approved by the two host institutional review boards.
Generation of patient-specific induced pluripotent stem cells, cardiac differentiation, and molecular characterization Skin fibroblasts were collected from dermal-biopsy of LQT2 patients and healthy subjects. Reprogramming was performed to generate iPSCs that were maintained on feeder-free condition as previously reported. 16 Eight to 10 clones were generated for each line and 2 to 3 clones from each cell line were used for the study, except for Case 5. Induced pluripotent stem cells were differentiated into iPSC-CMs using an embryoid body (EB)-based protocol as previously described. 16 For Western blots, coimmunoprecipitation (Co-IP), immunocytochemistry, and qRT-PCR analysis see Supplementary materials online.
Multielectrode array and calcium transient imaging
Multielectrode array (MEA) recordings were performed on EBs as previously described, 17 whereas calcium transients imaging was performed on isolated single iPSC-CMs using the Ca 2þ probe fluo-4-acetoxymethyl ester (Fluo-4AM) (see Supplementary materials online).
Statistical analysis
Results have been collected from at least three independent cardiac differentiations. Data were expressed as mean ± standard deviation and compared across groups by the Mann-Whitney U test or the KruskalWallis test, as appropriate, with Dunn's multiple comparison post hoc test. A P-value < 0.05 was considered statistically significant. Graphpad Prism (version 6) and Sigmaplot (version 12) were used for computations.
Results
Human induced pluripotent stem cellderived cardiomyocytes recapitulate long-QT syndrome type 2 phenotype
Human iPSC lines were generated from the fibroblasts of five patients bearing four different LQT2 mutations, S428X, R366X, A561V, IVS9-28A/G ( Figure 1A) , and from two healthy subjects. 8 Human iPSC clones stained positive for the pluripotent markers Oct4 and Tra-1-60 ( Figure 1B ; Supplementary material online, Figure S1 ) and Towards mutation-specific therapy for LQT2 patients expressed endogenous genes characteristic of pluripotency (see Supplementary material online, Figure S1 ) that confirmed conversion of patient fibroblasts to iPSCs. Each iPSC line was differentiated into iPSC-CMs expressing cardiac-specific genes (see Supplementary material online, Figure S2 ) and a-actinin positive sarcomeric striations ( Figure 1C ; Supplementary material online, Figure S2 ); these iPSC-CMs were able to contract by Day 14.
To assess whether patient-specific iPSC-CMs grossly recapitulate the LQT2 phenotype, MEA recordings were performed. Compared with controls, MEA analysis revealed a significant prolongation in corrected field potential duration (cFPD), used as a gross equivalent of QTc, across all LQT2 lines ( Figure 1D ; Table 2 ). Moreover, in wild type and diseased iPSC-CMs we recorded calcium transients under electrical pacing at 1 and 2 Hz ( Figure 1E ). Long-QT syndrome type 2 iPSC-CMs exhibited minor irregularities except Case 5, which showed abnormal waveforms at 1 Hz ( Figure 1E ). At 2 Hz pacing, the majority of LQT2 cardiomyocytes (70-90%) demonstrated abnormal calcium transient waveforms at rates ranging from 63 to 92 irregularities per minute ( Figure 1E ), suggesting that higher pacing frequencies could not be properly handled by LQT2 cells as they exacerbate Ca 2þ -handling irregularities and promote proarrhythmic events.
Lumacaftor retrafficks hERG in long-QT syndrome type 2 Class 2 mutants
As one of the main mechanisms of action of LUM is on protein trafficking, we investigated its effects on hERG protein translocation. Compared with controls, Case 1 and 2 (both Class 1 mutations) presented reduced levels of hERG at the membrane level but no significant peri-nuclear accumulation ( Figure 2A ; Supplementary material online, Figures S3 and S4) . In contrast, Case 3, 4, and 5 (all Class 2 mutations) presented reduced levels of hERG at the membrane level and a clear peri-nuclear accumulation pattern ( Figure 2A ; Supplementary material online, Figures S3 and S4) , which is typically observed in the presence of a trafficking defect. Treatment with 5 mM of LUM for 7 days did not change hERG pattern in Class 1 mutation carriers (Cases 1 and 2), but clearly reduced peri-nuclear accumulation of hERG along with increased membrane localization in Class 2 mutation carriers (Cases 3, 4, and 5) ( To obtain a functional readout of these changes, MEA was performed on all LQT2 iPSC-CMs, before and after 7 days of LUM treatment. While LUM significantly shortened cFPD (equivalent to QTc) by 30-40% in Case 3, 4, and 5 ( Figure 2C ; Table 3 ; Supplementary material online, Figure S5 ), we did not observe significant effects in Case 1, 2 and control ( Figure 2C ; Table 3 ; Supplementary material online, Figure S5 ). Cumulatively, these data strongly suggest that LUM can rescue hERG trafficking defects. In support of this hypothesis, patch clamping in single iPSC-CM showed a significant increase of I Kr current densities in a representative case of Class 2 LQT2 (Case 3 vs. Case 3 þ LUM: 0.21 ± 0.04 pA/pF vs. 0.46 ± 0.06 pA/pF at þ50mV, P = 0.001, n = 7, Supplementary material online, Figure S6 ).
Long-QT syndrome type 2 induced pluripotent stem cell-derived cardiomyocytes show abnormal calcium homeostasis Typically, LQT2 patients are advised to avoid sudden acoustic stimuli and sudden stresses when they are resting, since these stimuli facilitate cardiac arrhythmias through sympathetic activation.
2 This facilitation appears partly due to remodelling of Ca 2þ signalling pathways.
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We evaluated the effects of LUM on iPSC-CMs stimulated by 5 nM isoproterenol (ISO). LQT2 iPSC-CMs from Case 1 and 4 (representatives of Class 1 and 2 mutation, respectively) as well as Case 5 stimulated with ISO showed irregular calcium transients, and became almost incapable of being paced at a high stimulation frequency compared with control iPSC-CMs ( Figure 3A) . Lumacaftor treatment was able to reduce both calcium transient irregularities and their frequency ( Figure 3A) . Since abnormal calcium transient was detected in all LQT2 iPSCCMs at spontaneous beating rate and at 1 Hz, irrespective of mutation classes ( Figure 1E ), calcium transients were also evaluated at 2 Hz pacing before and after a chronic (7 days) treatment with LUM. While no significant changes were recorded in controls, LUM significantly reduced the percentage of LQT2 iPSC-CMs with irregular calcium transients as well as the rate of irregularities in Case 1 and 4 (representatives of Class 1 and 2 mutation, respectively) and Case 5 paced at 2 Hz ( Figure 3B ; Supplementary material online, Figure S7 ). Dispersion in the rate constant of decay was significantly reduced in LQT2 iPSC-CMs with LUM treatment compared with untreated LQT2 iPSC-CMs ( Figure 3B) .
These results suggest that in addition to its effect on hERG retrafficking, LUM might also have a stabilizing effect on intracellular calcium-handling machinery.
Lumacaftor stabilizes calcium regulatory network
To corroborate our observation regarding the effects of LUM on calcium transient abnormalities, we evaluated possible mechanisms involved in the regulation of calcium machinery. Human iPSC-CMs derived from controls, Case 2 (representative of Class 1 mutation) and Case 3 (representative of Class 2 mutation) were stimulated with isoproterenol (ISO, 5 nM) before or after LUM treatment. Western blot analysis revealed that ISO stimulation induced phosphorylation of phospholamban and RyR2 as well as increased total protein kinase A (PKA), confirming b-adrenergic stimulation ( Figure  4A ; Supplementary material online, Figure S8 ). Although LUM had no significant effect on phospholamban phosphorylation, it significantly reduced RyR2 phosphorylation and increased expression of the cardiac membrane receptor integrin b1D across controls and both LQT2 iPSC-CM lines tested ( Figure 4A) . Furthermore, LUM treatment significantly enhanced the levels of phosphorylated protein phosphatase A1 (PP1) 18 and PKA, which regulate RyR2 dephosphorylation and phosphorylation, 19 respectively (see Supplementary Figure 4B ).
Immunostaining analysis further validated these results: indeed, we observed increased co-localization of integrin b1D with a-actinin and wheat germ agglutinin in LQT2 iPSC-CMs treated with LUM compared with untreated cardiomyocytes ( Figure 4C ; Supplementary material online, Figure S9 ). Based on our observations, we hypothesize that LUM increases the interaction between integrin b1D and RyR2 while reducing its phosphorylation; this mechanism may decrease the probability of RyR2 openings, 21 thus limiting spontaneous calcium releases from the SR and, as a consequence, calcium transient abnormalities and proarrhythmic events.
Lumacaftor is more effective than b-blockers in preventing arrhythmias
Lastly, we compared the efficacy of LUM vs. nadolol (5 mM), a drug currently used to treat LQT2 patients 2 but which has no effects on ), ryanodine receptor 2 and its phosphorylated form (RyR2 and pRyR2 S2808 ), Serca2a and L-type calcium channel along with integrin b1D (b1D), the cardiac marker cTnT and internal control GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) were evaluated. Bottom panel shows normalized densitometric analysis for these markers post-various treatments. Data represent mean ± standard deviation of three independent experiments.ˆ= P < 0.05 and * = P < 0.05 vs. Figure S10 ). When pacing was ramped up to 1.5 Hz, several transient abnormalities were observed in all three lines, with Case 5 showing the highest irregularity rates. When pacing was further ramped to 2 Hz, all iPSCCMs demonstrated calcium transient abnormalities ( Figure 5 , Supplementary material online, Figure S10 ). Treatment with nadolol did not show any significantly reduction of calcium irregularities at 1.5 Hz or 2 Hz in all three cases tested ( Figure 5 , Supplementary material online, Figure S10 ). In contrast, treatment with LUM significantly reduced calcium transient abnormalities at both 1.5 and 2 Hz in all LQT2 iPSC-CMs studied ( Figure 5 , Supplementary material online, Figure S10 ). These results support the notion that LUM may prevent calcium transient abnormalities in both Class 1 and Class 2 LQT2 mutations.
Discussion
The present study demonstrates that LUM has the potential of being beneficial for the management of LQT2 patients, especially those carrying a Class 2 mutation. Our findings are not based on animal models but on cardiomyocytes derived from iPSC of LQT2 patients presenting severe clinical manifestations and may represent a significant breakthrough for a more targeted therapeutic approach of this disease. What makes this finding truly exciting for those involved in the clinical management of LQTS is the fact that LUM is already in clinical use, thus its safety profile is already known.
Slow progress in the therapy for long-QT syndrome and long-QT syndrome type 2
When large numbers of symptomatic LQTS patients are left untreated, within 1 year of the first syncope their mortality rate is as high as 21%. 22 The evolution in pharmacological and surgical antiadrenergic therapy, complemented when appropriate by ICD implantation, has dramatically reduced the mortality rate to about 1% over a 15-year follow-up. 2 However, there is a clear mismatch between the rapid progress made in genetics since 1995 23 and the very slow evolution in personalized therapy. Since the first attempt to treat LQTS with digitalis, the main advancement has come from the concept of interfering with the arrhythmogenic trigger, namely sympathetic activation leading primarily to norepinephrine release. 1, 22 This has resulted in the successful use of b-blockers and of left cardiac sympathetic denervation. 24 Despite their effectiveness, these therapies have the conceptual limitation of a generic antagonism with the trigger. Similarly, the ICD represents a conceptually gross intervention aimed at terminating an already initiated arrhythmia. A more intellectually rewarding progress came with the first gene-specific therapy when the sodium channel blocker mexiletine was proposed for LQT3 patients. 25 The novelty brought by the present study is that of a novel potential therapy aimed at correcting an arrhythmogenic mechanism specific for an important class of mutations causing LQT2, a form incompletely protected by anti-adrenergic therapies. 2, 26 The concept here is to target the trafficking defect characteristic of specific mutations with the goal of obtaining a more effective anti-arrhythmic therapy.
The role of mutation classes Class 1 (40%) and Class 2 mutations (55%), acting through lossof-function mechanisms, 10 account for the majority of the over 400 reported pathogenic LQT2 mutations. Arrhythmias in LQT2 patients are triggered mostly during sleep/rest (sudden noise, startle) when an abrupt release of norepinephrine occurs while the heart rate is relatively low. 2 Norepinephrine release activates b-adrenergic receptors which signal downstream via cAMP-dependent PKA, leading to RyR2 hyper-phosphorylation and enhanced SR calcium release as arrhythmia trigger. 21 However, in Class 2 patients a defect in the trafficking of hERG from the cytoplasm to the cell membrane plays a pivotal role. Thus, a possible strategy to treat LQT2 may be to correct the processing of misfolded hERG. Lumacaftor is a novel drug, already in clinical use, able to enhance the processing of misfolded CFTR, to increase chloride secretion in human bronchial epithelial cells and to benefit patients affected by cystic fibrosis when used in combination with ivacaftor. 12, 27, 28 Based on these results, we hypothesized that LUM might act also on hERG trafficking defect, thus shortening the repolarization time of cardiac cells derived from LQT2 patients carrying a Class 2 mutation. To prove our hypothesis, we evaluated the efficacy of LUM on Class 2 LQT2 iPSC-CMs and demonstrated a shortening of cFPD, an equivalent of QTc. As expected, we did not observe similar effects in iPSCCMs from Class 1 patients, since in these patients the mutation leads to a nonsense-mediated decay without a defect in hERG trafficking. 10 The association of QT prolongation with increased risk of SCD in general population 29 has served as a thrust for genome-wide studies in large population cohorts to develop better gene-specific drugs for therapeutic regimes. While such studies have identified various genes such as KCNQ1, KCNH2, and SCN5A, a surprising large number of novel genetic loci were found in or around genes regulating calcium handling, such as SERCA, PLN, and NCX1, which along with RYR2 are vital for the normal calcium homeostasis and contraction coupling in the heart. 30 Based on these previous reports, we evaluated the effect of LUM in regulating calcium homeostasis in LQT2 iPSC-CMs. Our results demonstrate that LUM can reduce calcium-handling abnormalities present in all diseased iPSC-CMs studied. The prolonged repolarization and the consequent disrupted ionic balance in LQT2 may alter the machinery of calcium regulation by hyper-phosphorylation of RyR2, 11 resulting in heightened SR calcium leakage 21 and subsequent contractile dysfunctions and arrhythmogenesis. 31 Our results show that LUM treatment reduces RyR2 phosphorylation in LQT2 cardiomyocytes and suppress irregular calcium following isoproterenol challenge (or during high-frequency pacing) in both Class 1 and Class 2 mutation. It has been recently shown that LUM modulates cytoskeletal reorganization via PKA activation in CFTR mutants. 32 We observed that LUM can enhance the phosphorylation of PKA and the expression of integrin b1D, an adhesive receptor needed for the stabilization of the sarcomere. Moreover, our results also suggest that reduced RyR2 phosphorylation and enhanced interaction with integrin b1D could be one of the key mechanisms through which LUM leads to prevention of calcium transient abnormalities in LQT2 iPSC-CMs. While the role of integrins in cardiomyocytes is not fully understood, it is surmised that RyR2 interacts with integrins to reduce mitochondrial calcium loading by altering calcium availability from SR, 33 leading to reduced calcium influx. 34 These observations raise the untested possibility that LUM might be of value for the complex management of catecholaminergic polymorphic ventricular tachycardia, and perhaps for more common conditions in which calcium-mediated arrhythmias play a role. However, further studies will be necessary to validate this last hypothesis and to confirm our observations on the effects of LUM on calcium transients in other severe congenital arrhythmias.
Conclusion
We have provided evidence suggesting that LUM might represent an effective therapy for the mutation-specific management of certain LQT2 patients not protected by b-blockers. Extreme caution is always warranted when extrapolating experimental finding to the adult human heart. However, the fact that the safety profile of LUM is already known represents the first milestone for the translation of our findings to the bedside.
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